Investigating the immune mechanisms underlying TKI resistance and exploring potential synergies with combination immunotherapy could enhance crizotinib’s therapeutic impact on NSCLC patients with ROS1 fusion. Here, ROS1 is linked to non-small cell lung carcinoma.